Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Smilax glabra is a perennial climbing plant native to China and parts of Asia. Its rhizome (root) is widely used in traditional Chinese medicine under the name 土茯苓 (tufuling) and also known as chinaroot or sarsaparilla. The dried root is typically prepared as a decoction for oral use. It has been traditionally used to treat conditions such as dysentery, joint pain (including arthritis and rheumatism), colds, skin diseases like psoriasis, syphilis and other infections[1][3][4][5]. Pharmacologically active compounds identified in Smilax glabra include dihydro-flavonol glycosides (such as astilbin), phenylpropanoid-substituted epicatechins (smiglabrone A/B), and steroidal sapogenins like sarsasapogenin[3]. Preclinical studies suggest anti-inflammatory effects via downregulation of inflammatory cytokines such as IL-1β, TNF-α, and IL-6; immunomodulatory activity; antimicrobial properties; antipsoriatic effects through inhibition of Th17 cell differentiation; hepatoprotective actions; and possible anticancer potential[1][4]. However, robust clinical evidence for these uses remains limited.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on smilax glabra.